AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo | Citedby Results | Cellular Physiology and Biochemistry | Karger Publishers

Skip to Main Content

Skip Nav Destination

AZD5153 Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo

Cellular Physiology and Biochemistry (2018) 50 (2): 798–809.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer

Abhishek Wahi
Namish Manchanda
Priti Jain
Hemant R Jadhav

Bioorganic Chemistry (2023) 140: 106833.

Role of bromodomain and extraterminal (BET) proteins in prostate cancer

Adel Mandl
Mark C. Markowski
Michael A. Carducci
Emmanuel S. Antonarakis

Expert Opinion on Investigational Drugs (2023) 32 (3): 213.

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

Erika P. Hamilton
Judy S. Wang
Amit M. Oza
Manish R. Patel
Susanna V. Ulahannan
Todd Bauer
Janet L. Karlix
Jorge Zeron-Medina
Giulia Fabbri
Paola Marco-Casanova
Ganesh Moorthy
Maureen M. Hattersley
Gillian M. Littlewood
Patrick Mitchell
Jamal Saeh
Gayle P. Pouliot
Kathleen N. Moore

Molecular Cancer Therapeutics (2023) 22 (10): 1154.

Rational design, synthesis and biological evaluation of benzo[d]isoxazole derivatives as potent BET bivalent inhibitors for potential treatment of prostate cancer

Junhua Li
Run Zhu
Xiaoxi Zhuang
Cheng Zhang
Hui Shen
Xishan Wu
Maofeng Zhang
Cen Huang
Qiuping Xiang
Linxiang Zhao
Yong Xu
Yan Zhang

Bioorganic Chemistry (2023) 135: 106495.

AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells

Cho-Hao Lin
Jimmy Chun-Tien Kuo
Ding Li
Aaron B. Koenig
Alexander Pan
Pearlly Yan
Xue-Feng Bai
Robert J. Lee
Kalpana Ghoshal

Frontiers in Cell and Developmental Biology (2022) 10

From Therapy Resistance to Targeted Therapies in Prostate Cancer

Filipa Moreira-Silva
Rui Henrique
Carmen Jerónimo

Frontiers in Oncology (2022) 12

Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer

Anna E. Harris
Veronika M. Metzler
Jennifer Lothion-Roy
Dhruvika Varun
Corinne L. Woodcock
Daisy B. Haigh
Chantelle Endeley
Maria Haque
Michael S. Toss
Mansour Alsaleem
Jenny L. Persson
Lorraine J. Gudas
Emad Rakha
Brian D. Robinson
Francesca Khani
Laura M. Martin
Jenna E. Moyer
Juliette Brownlie
Srinivasan Madhusudan
Cinzia Allegrucci
Victoria H. James
Catrin S. Rutland
Rupert G. Fray
Atara Ntekim
Simone de Brot
Nigel P. Mongan
Jennie N. Jeyapalan

Frontiers in Endocrinology (2022) 13

BET Proteins as Attractive Targets for Cancer Therapeutics

Joanna Sarnik
Tomasz Popławski
Paulina Tokarz

International Journal of Molecular Sciences (2021) 22 (20): 11102.

Mission Possible: Advances in MYC Therapeutic Targeting in Cancer

Brittany L. Allen-Petersen
Rosalie C. Sears

BioDrugs (2019) 33 (5): 539.